JP2020505426A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505426A5
JP2020505426A5 JP2019541403A JP2019541403A JP2020505426A5 JP 2020505426 A5 JP2020505426 A5 JP 2020505426A5 JP 2019541403 A JP2019541403 A JP 2019541403A JP 2019541403 A JP2019541403 A JP 2019541403A JP 2020505426 A5 JP2020505426 A5 JP 2020505426A5
Authority
JP
Japan
Prior art keywords
lung cancer
item
cell
smarca2
smarca4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019541403A
Other languages
English (en)
Japanese (ja)
Other versions
JP7324144B2 (ja
JP2020505426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/016562 external-priority patent/WO2018144798A1/en
Publication of JP2020505426A publication Critical patent/JP2020505426A/ja
Publication of JP2020505426A5 publication Critical patent/JP2020505426A5/ja
Priority to JP2022210528A priority Critical patent/JP2023026523A/ja
Application granted granted Critical
Publication of JP7324144B2 publication Critical patent/JP7324144B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019541403A 2017-02-02 2018-02-02 癌処置様式 Active JP7324144B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022210528A JP2023026523A (ja) 2017-02-02 2022-12-27 癌処置様式

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762453929P 2017-02-02 2017-02-02
US62/453,929 2017-02-02
US201762479878P 2017-03-31 2017-03-31
US62/479,878 2017-03-31
PCT/US2018/016562 WO2018144798A1 (en) 2017-02-02 2018-02-02 Cancer treatment modalities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022210528A Division JP2023026523A (ja) 2017-02-02 2022-12-27 癌処置様式

Publications (3)

Publication Number Publication Date
JP2020505426A JP2020505426A (ja) 2020-02-20
JP2020505426A5 true JP2020505426A5 (cg-RX-API-DMAC7.html) 2021-03-18
JP7324144B2 JP7324144B2 (ja) 2023-08-09

Family

ID=63041113

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019541403A Active JP7324144B2 (ja) 2017-02-02 2018-02-02 癌処置様式
JP2022210528A Pending JP2023026523A (ja) 2017-02-02 2022-12-27 癌処置様式

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022210528A Pending JP2023026523A (ja) 2017-02-02 2022-12-27 癌処置様式

Country Status (6)

Country Link
US (2) US20190350929A1 (cg-RX-API-DMAC7.html)
EP (1) EP3576729A4 (cg-RX-API-DMAC7.html)
JP (2) JP7324144B2 (cg-RX-API-DMAC7.html)
CN (1) CN110366413A (cg-RX-API-DMAC7.html)
AU (1) AU2018217139A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018144798A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム,インコーポレイティド 癌を処置するための併用療法
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
CA3177444A1 (en) * 2020-05-28 2021-12-02 Carly CAMPBELL Use of ezh2 inhibitors for treating cancer
WO2023196963A1 (en) * 2022-04-08 2023-10-12 The Regents Of The University Of California Combination metabolic-epigenetic treatment for early lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140296248A1 (en) * 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2836216B1 (en) * 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
KR20190105669A (ko) * 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
WO2014092905A1 (en) 2012-12-10 2014-06-19 Children's Medical Center Corporation Methods and assays for combination treatment of cancer
US20160326596A1 (en) 2013-12-31 2016-11-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
US20180296563A1 (en) * 2015-09-25 2018-10-18 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor
US20190038633A1 (en) 2016-02-08 2019-02-07 Epizyme, Inc. Methods of treating cancer
CN109312407A (zh) * 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法

Similar Documents

Publication Publication Date Title
Ng et al. RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Sidders et al. Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response
Herbst et al. The biology and management of non-small cell lung cancer
Martini et al. Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events
Herbst et al. Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC
CN109890982B (zh) 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
Karimkhani et al. A review of novel therapies for melanoma
Ali et al. PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Ai et al. Current issues in malignant pleural mesothelioma evaluation and management
WO2018223040A1 (en) Methods of treating a tumor using an anti-pd-1 antibody
JP2018502828A5 (cg-RX-API-DMAC7.html)
Paz‐Ares et al. Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
US20240125787A1 (en) Sting levels as a biomarker for cancer immunotherapy
Visser et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study
Bai et al. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
JP2018529698A5 (cg-RX-API-DMAC7.html)
US20200277387A1 (en) Methods and compositions for treating cancer
Hu et al. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Algazi et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
Jia et al. Serine protease inhibitor kazal type 1, a potential biomarker for the early detection, targeting, and prediction of response to immune checkpoint blockade therapies in hepatocellular carcinoma
Lazzari et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors
Mourah et al. Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma
Podevin et al. Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France
Zhu et al. Population-specific immunogenomic alterations in gallbladder cancer and prognostic significance
Chen et al. Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan